Although local hyperthermia is used clinically as an adjunct to cancer therapy, there is currently no direct clinical evidence confirming that this approach enhances HSP-mediated immunogenicity or IFN-γ-driven immune responses in patients. This evidence concerns the gene HSP90B2P and cancer.